Wednesday, April 12, 2017
1CellBiO Inc announced today a research collaboration with UCB to validate and deploy the inDrop™ high throughput single cell RNA sequencing platform in order to better understand the cellular composition of complex tissues, and to assess cellular responses to novel and existing therapies."We are pleased to enter into this agreement with a world-leading drug discovery and development company like UCB," said Colin J.H. Brenan, Ph.D., Chief Executive Officer. "It is an important validation of our efforts to develop inDrop™ applications for pharmaceutical research and clinical development."